聚焦高增长赛道，美敦力2026将加速补强型并购！

制药网02-10

近年来，医疗行业竞争的加剧让相关企业的并购整合开始不断加速。据悉，2026年开始不到2个月，美敦力就已接连宣布了1 笔正式收购和1 项重大战略投资，均聚焦心血管领域，旨在强化其在结构性心脏病和 AI 诊断技术的优势地位。如近日，美敦力宣布，已行使选择权，以5.85亿美元(折合人民币约40.6亿元)对CathWorks公司进行收购。资料显示，CathWorks专注于开发基于计算机视觉和人工智能技术的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2610623426?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-10 10:47","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2610623426","market":"us","top_or_hot":-1,"title":"聚焦高增长赛道，美敦力2026将加速补强型并购！","media":"制药网","content":"<div>\n<p>近年来，医疗行业竞争的加剧让相关企业的并购整合开始不断加速。据悉，2026年开始不到2个月，美敦力就已接连宣布了1 笔正式收购和1 项重大战略投资，均聚焦心血管领域，旨在强化其在结构性心脏病和 AI 诊断技术的优势地位。如近日，美敦力宣布，已行使选择权，以5.85亿美元(折合人民币约40.6亿元)对CathWorks公司进行收购。资料显示，CathWorks专注于开发基于计算机视觉和人工智能技术的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210104906a6e874fd&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>聚焦高增长赛道，美敦力2026将加速补强型并购！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n聚焦高增长赛道，美敦力2026将加速补强型并购！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-10 10:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210104906a6e874fd&s=b><strong>制药网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近年来，医疗行业竞争的加剧让相关企业的并购整合开始不断加速。据悉，2026年开始不到2个月，美敦力就已接连宣布了1 笔正式收购和1 项重大战略投资，均聚焦心血管领域，旨在强化其在结构性心脏病和 AI 诊断技术的优势地位。如近日，美敦力宣布，已行使选择权，以5.85亿美元(折合人民币约40.6亿元)对CathWorks公司进行收购。资料显示，CathWorks专注于开发基于计算机视觉和人工智能技术的...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210104906a6e874fd&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1244550577.SGD","symbol_name":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210104906a6e874fd&s=b","article_id":"2610623426","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210104906a6e874fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610623426","pubTimestamp":1770691669,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据了解，自2018年起，美敦力便持有CathWorks的少数股权。2022年，美敦力与其建立了战略合作伙伴关系。同时，与美敦力现有冠脉介入产品形成技术互补，进一步提升导管室效率和诊断准确性。1月20日，美敦力宣布对Anteris Technologies进行高达9000万美元的战略投资，以期接入其DurAVR仿生瓣膜技术。交易完成后，美敦力将持有Anteris约16.0%至19.99%的股权，并获得董事会非投票观察员席位，同时在未来潜在的第三方并购提案中，享有“特定谈判权利”。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1","LU0314106906.USD":"MANULIFE GF GLOBAL EQUITY \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU0211326839.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","BK4082":"医疗保健设备","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU2089283258.USD":"安联环球可持续基金Cl AM Dis","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU0976567544.SGD":"FTIF - Templeton Global Income A Mdis SGD-H1","BK4588":"碎股","MDT":"美敦力","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","IE00BQXX3C00.GBP":"GUINNESS GLOBAL INNOVATORS \"C\" (GBP) ACC","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H"},"translate_title":"Focusing on the high-growth track, Medtronic will accelerate reinforcing mergers and acquisitions in 2026!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDT":1.5},"content_text":"近年来，医疗行业竞争的加剧让相关企业的并购整合开始不断加速。据悉，2026年开始不到2个月，美敦力就已接连宣布了1 笔正式收购和1 项重大战略投资，均聚焦心血管领域，旨在强化其在结构性心脏病和 AI 诊断技术的优势地位。如近日，美敦力宣布，已行使选择权，以5.85亿美元(折合人民币约40.6亿元)对CathWorks公司进行收购。资料显示，CathWorks专注于开发基于计算机视觉和人工智能技术的心血管影像和治疗解决方案，致力于为经皮冠状动脉介入治疗(PCI)决策提供客观数据。据了解，自2018年起，美敦力便持有CathWorks的少数股权。2022年，美敦力与其建立了战略合作伙伴关系。而通过本次收购，CathWorks 将并入美敦力冠脉及肾去神经业务，成为 \"影像到介入\" 一体化平台的核心诊断引擎。同时，与美敦力现有冠脉介入产品形成技术互补，进一步提升导管室效率和诊断准确性。1月20日，美敦力宣布对Anteris Technologies进行高达9000万美元的战略投资，以期接入其DurAVR仿生瓣膜技术。交易完成后，美敦力将持有Anteris约16.0%至19.99%的股权，并获得董事会非投票观察员席位，同时在未来潜在的第三方并购提案中，享有“特定谈判权利”。Anteris核心产品DurAVR是一款球囊扩张式仿生经导管主动脉瓣膜(THV)，其设计目标是模拟健康人体主动脉瓣的血流动力学性能，该产品采用公司独有的抗钙化牛组织技术Adapt™制成。目前，Anteris 正在推进针对重度主动脉瓣狭窄(AS)患者的 DurAVR 全球关键性临床试验(Paradigm Trial)。值得一提的是，此次美敦力投资，距离Anteris 公布体式仿生TAVR DurAVR一年期积极临床结果仅过去三个月。这显示出，美敦力十分看好DurAVR技术 。鉴于美敦力过去五年公司完成了11-12起嵌入式收购，重点布局心脏恢复、电生理技术及糖尿病领域，以及2026年初的这两笔收购投资来看，业内分析认为，当前心脏消融和手术 机器人是医疗器械行业增长较快的细分领域，因此美敦力在传统业务面临市场饱和与价格压力下，为了突破增长瓶颈正通过并购快速切入以上并扩大市场份额。实际上，美敦力高管也曾公开表态，公司已完成运营优化，\" 有能力且有充足资金 \"开展多笔并购，目标是\" 低至中个位数 10 亿美元规模 \" 的补强型交易，特别关注心脏病学和神经科学领域。基于美敦力高管公开表态与行业动态，业内预计 其在2026-2027 年还将完成 3-5 笔战略收购，进一步优化产品组合，提升盈利能力与估值水平，快速兑现增长，成为医疗器械行业 \"精准并购 + 战略聚焦\" 发展的表率。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610623426","isCrawlerRequest":true}